Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Colombat

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Blood|September 10, 2005
A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 casesSophie Camilleri-Broët, Emmanuelle Crinière, Philippe Broët, et al.
Clinical Lymphoma|January 11, 2003
Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study GroupClaude Linassier, Bernard Desablens, Thierry Lefrancq, et al.
American Journal of Hematology|July 24, 2014
A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trialGaelle Olivier, Aline Clavert, Laurence Lacotte-Thierry, et al.
Experimental Hematology|January 25, 2003
Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrowLotfi Benboubker, Guillaume Cartron, Françoise Roingeard, et al.
Annals of Hematology|January 8, 2020
Hypercalcemia is associated with a poor prognosis in lymphoma a retrospective monocentric matched-control study and extensive review of published reported casesNicolas Vallet, Marjan Ertault, Jean-Baptiste Delaye, et al.
The Oncologist|October 10, 2013
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphomaAndré Bosly, Andrew Grigg, Harald Holte, et al.
Bulletin Du Cancer|July 30, 2004
[For a coordination of the supportive care for people affected by severe illnesses: proposition of organization in the public and private health care centres]Ivan Krakowski, François Boureau, Roland Bugat, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 21, 2015
Emergence of community-acquired Clostridium difficile infection: the experience of a French hospital and review of the literatureMaja Ogielska, Philippe Lanotte, Cécile Le Brun, et al.
Leukemia & Lymphoma|June 12, 2012
Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiationNina Arakelyan, Jean-Philippe Jais, Cécile Tomowiack, et al.
British Journal of Haematology|August 27, 2010
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95Audrey Simon, Michel Peoch, Philippe Casassus, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Blood|September 10, 2005
A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 casesSophie Camilleri-Broët, Emmanuelle Crinière, Philippe Broët, et al.
Clinical Lymphoma|January 11, 2003
Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study GroupClaude Linassier, Bernard Desablens, Thierry Lefrancq, et al.
American Journal of Hematology|July 24, 2014
A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trialGaelle Olivier, Aline Clavert, Laurence Lacotte-Thierry, et al.
Experimental Hematology|January 25, 2003
Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrowLotfi Benboubker, Guillaume Cartron, Françoise Roingeard, et al.
Annals of Hematology|January 8, 2020
Hypercalcemia is associated with a poor prognosis in lymphoma a retrospective monocentric matched-control study and extensive review of published reported casesNicolas Vallet, Marjan Ertault, Jean-Baptiste Delaye, et al.
The Oncologist|October 10, 2013
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphomaAndré Bosly, Andrew Grigg, Harald Holte, et al.
Bulletin Du Cancer|July 30, 2004
[For a coordination of the supportive care for people affected by severe illnesses: proposition of organization in the public and private health care centres]Ivan Krakowski, François Boureau, Roland Bugat, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 21, 2015
Emergence of community-acquired Clostridium difficile infection: the experience of a French hospital and review of the literatureMaja Ogielska, Philippe Lanotte, Cécile Le Brun, et al.
Leukemia & Lymphoma|June 12, 2012
Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiationNina Arakelyan, Jean-Philippe Jais, Cécile Tomowiack, et al.
British Journal of Haematology|August 27, 2010
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95Audrey Simon, Michel Peoch, Philippe Casassus, et al.
Pageof 7